Search Results - "Culp JS"

Viro3D: a comprehensive database of virus protein structure predictions.

Authors: Litvin, Ulad Lytras, Spyros Jack, Alexander et al.

Source: Molecular Systems Biology. Nov2025, Vol. 21 Issue 11, p1599-1617. 19p.

Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization.

Authors: Aljedani, Safia S. Liban, Tyler J. Tran, Karen et al.

Source: PLoS Pathogens. 9/24/2021, Vol. 17 Issue 9, p1-24. 24p.

PDE4 inhibitor rolipram dynamically regulates the balance between D1-MSNs and D2-MSNs in the DMS to modulate abnormal "Go" behavior associated with alcohol addiction.

Authors: Zhao W Zhao S Wang ZQ et al.

Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 Jun; Vol. 47 (6), pp. 1501-1516. Date of Electronic Publication: 2026 Feb 06.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE

In Silico Design and Experimental Validation of Novel Oxazole Derivatives Against Varicella zoster virus.

Authors: Kovalishyn, Vasyl Severin, Oleksandr Kachaeva, Maryna et al.

Source: Molecular Biotechnology. Apr2024, Vol. 66 Issue 4, p707-717. 11p.

Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [¹⁸F]JNJ42259152 PET study in rats.

Authors: de Laat, Bart Kling, Yvonne E. Schroyen, Gwen et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jan2022, Vol. 49 Issue 2, p492-502. 11p. 1 Color Photograph, 4 Graphs.

Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study.

Authors: Peng, Jia Liu, Ming-Ming Liu, Hui-Hui et al.

Source: Thrombosis Journal. 11/22/2021, Vol. 19 Issue 1, p1-13. 13p.

Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation.

Authors: Yu X Plotnikova O Bonin PD et al.

Source: ELife [Elife] 2019 Oct 03; Vol. 8. Date of Electronic Publication: 2019 Oct 03.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE

A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.

Authors: Yurgelun-Todd, Deborah A. Renshaw, Perry F. Goldsmith, Paul et al.

Source: Psychopharmacology. Feb2020, Vol. 237 Issue 2, p317-328.

Functional analysis of natural PCSK9 mutants in modern and archaic humans.

Authors: Mikaeeli, Sepideh Susan‐Resiga, Delia Girard, Emmanuelle et al.

Source: FEBS Journal. Feb2020, Vol. 287 Issue 3, p515-528. 14p.

Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir.

Authors: Ichikawa, Tatsuki Miyaaki, Hisamitsu Miuma, Satoshi et al.

Source: Biomedical Reports. Mar2019, Vol. 10 Issue 3, p1-9. 9p.

The role of circadian rhythm in the regulation of cellular protein profiles in the brain.

Authors: BEKER, Mustafa Çağlar KILIÇ, Ertuğrul

Source: Turkish Journal of Medical Sciences. 2021, Vol. 51 Issue 5, p2705-2715. 11p.

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.

Authors: Tsai, Max Chrones, Lambros Xie, Jinhui et al.

Source: Psychopharmacology. Oct2016, Vol. 233 Issue 21/22, p3787-3795.

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.

Authors: Seidah, Nabil G.¹ seidahn@ircm.qc.ca

Source: Global Cardiology Science & Practice. 2015, Vol. 2015 Issue 4, p1-19. 19p.

In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors: Redrobe, John Jørgensen, Morten Christoffersen, Claus et al.

Source: Psychopharmacology. Aug2014, Vol. 231 Issue 16, p3151-3167.

Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.

Authors: Gresack, Jodi Seymour, Patricia Schmidt, Christopher et al.

Source: Psychopharmacology. May2014, Vol. 231 Issue 10, p2189-2197.

Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

Authors: Kuroiwa, Mahomi Snyder, Gretchen Shuto, Takahide et al.

Source: Psychopharmacology. Feb2012, Vol. 219 Issue 4, p1065-1079.

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.

Authors: Weber, M. Breier, M. Ko, D. et al.

Source: Psychopharmacology. May2009, Vol. 203 Issue 4, p723-735.

Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors: Reneerkens, Olga Rutten, Kris Steinbusch, Harry et al.

Source: Psychopharmacology. Jan2009, Vol. 202 Issue 1-3, p419-443.

Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Authors: Siuciak, Judith A. Chapin, Douglas S. McCarthy, Sheryl A. et al.

Source: Psychopharmacology. Jun2007, Vol. 192 Issue 3, p415-424.

Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells.

Authors: Mousavi, Seyed A. Berge, Knut E. Berg, Trond et al.

Source: FEBS Journal. Aug2011, Vol. 278 Issue 16, p2938-2950. 13p.